Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Elena Tamagno[1]

1 University of Turin

Potential competing interests: No potential competing interests to declare.

LUXM7W

Title: **Targe&ng Alzheimer´s disease hallmarks with the Nrf2 activator Isoeugenol**

Authors: Ana Silva et al

The results reported that Isoeugenol demonstrated a neuroprotective profile in both in vitro and in vivo models of

AD, highlighting its therapeutic potential for the treatment of this disease, which should be further explored.

The paper is well written and complete.

Just a small observation:

The AKT /GSK3beta signaling pathway was evaluated only in the in vitro model. Given the significance of the role of kinases in general, and of GSK3 beta in particular, in the hyperphosphorylation of Tau, it would also be appropriate to evaluate it in the in vivo model. We believe that this data would increase the possible interest of this molecule for therapeutic purposes .